Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
4.670
-0.070 (-1.48%)
At close: May 14, 2026, 4:00 PM EDT
4.620
-0.050 (-1.07%)
After-hours: May 14, 2026, 4:59 PM EDT
Bicycle Therapeutics Employees
Bicycle Therapeutics had 288 employees as of December 31, 2025. The number of employees decreased by 17 or -5.57% compared to the previous year.
Employees
288
Change (1Y)
-17
Growth (1Y)
-5.57%
Revenue / Employee
$220,472
Profits / Employee
-$760,490
Market Cap
325.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 288 | -17 | -5.57% |
| Dec 31, 2024 | 305 | 21 | 7.39% |
| Dec 31, 2023 | 284 | 48 | 20.34% |
| Dec 31, 2022 | 236 | 117 | 98.32% |
| Dec 31, 2021 | 119 | 32 | 36.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Abeona Therapeutics | 226 |
| Silence Therapeutics | 88 |
| Lineage Cell Therapeutics | 77 |
| Armata Pharmaceuticals | 60 |
| Immuneering | 53 |
| Compass Therapeutics | 39 |
| Inhibikase Therapeutics | 35 |
BCYC News
- 14 days ago - Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies - TheFly
- 14 days ago - Bicycle Therapeutics reports Q1 EPS (87c), consensus (65c) - TheFly
- 14 days ago - Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Business Wire
- 23 days ago - Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting - Business Wire
- 24 days ago - Bicycle Therapeutics announces updates from EphA2 pipeline at AACR meeting - TheFly
- 24 days ago - Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026 - Business Wire
- 5 weeks ago - Bicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley - TheFly
- 2 months ago - Bicycle Therapeutics price target lowered to $7 from $11 at RBC Capital - TheFly